Gates Package — page 256

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Mike Vincent, M.D., Ph.D. Senior Vice President and Chief Scientific Officer of the Inflammation and Immunology Research Unit Pfizer Gail Weinmann, M.D. Deputy Director, Division of Lung Diseases National Heart, Lung, and Blood Institute, NIH Vaccines Working Group Paula Annunziato, M.D. Vice President and Therapeutic Area Head, Vaccines Clinical Research Merck & Co., Inc. Ann Arvin, M.D. Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology Stanford University School of Medicine Beth Bell, M.D. Clinical Professor, Global Health University of Washington Susan Buchbinder, M.D. Clinical Professor of Medicine, University of California, San Francisco; Director of HIV Prevention Research, San Francisco Department of Public Health Marco Cavaleri, Ph.D. Head, Biological Health Threats and Vaccines Strategy European Medicines Agency Lawrence Corey, M.D. Professor, Departments of Laboratory Medicine & Medicine Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences President & Director Emeritus Fred Hutchinson Cancer Research Center Mark Davis, Ph.D. Professor, Microbiology and Immunology Director, Stanford Institute for Immunology, Transplantation and Infection Stanford University School of Medicine Emilio Emini, Ph.D. Director, TB & HIV Program Bill & Melinda Gates Foundation Gregory Glenn, M.D. Chief Scientific Officer